GAS2 has previously been linked to CML disease progression, cell cycle control, apoptosis, and response to Imatinib (Janssen et al., 2005; Radich et al., 2006; Zhou et al., 2014). Here, GAS2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.